Factor Model (net -0.3)
Factor Model
net -0.3 1.2 / 10Biohaven insiders buy $17M, targets rise
Watch: Phase 3 opakalim trial readout in the second half of 2026 will be crucial for validating pipeline progress and driving valuation.
Biohaven insiders made large purchases totaling about $17M recently, including $8M by John Childs and $5M by Vladimir Coric at around $41 per share. Canaccord initiated coverage with a Buy and $21 target; Citi upgraded BHVN's target to $17 from $14. The company focuses on novel therapeutics in obesity, neuroscience, and oncology, with a Phase 3 opakalim trial readout expected H2 2026.
Significant insider buying combined with analyst upgrades signals strong confidence in Biohaven's drug pipeline and near-term catalysts despite the stock's high volatility and ongoing losses.
Evidence
7 older signals
Fundamentals & Data ▾
Recent transactions
Get alerted when BHVN changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.